Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image of ICU environment featuring automated cerebrospinal fluid management equipment. BrainSpace’s Intellidrop device, recently cleared by the FDA, aims to modernize CSF drainage and pressure monitoring for neurocritical care patients.
Medical Devices & Diagnostics

BrainSpace wins FDA nod for automated brain fluid system—what this means for ICUs

BrainSpace, a U.S.-based medical technology company, has received 510(k) clearance from the U.S. Food and Drug Administration for Intellidrop, a fully automated cerebrospinal fluid (CSF) drainage and intracranial pressure (ICP) monitoring system. The cleared indication covers ventricular or lumbar use in patients requiring external CSF drainage and continuous pressure monitoring—making it potentially relevant across a

Read More
Representative image showing radiation-induced skin toxicity, a growing challenge in oncology care. Hoth Therapeutics is targeting this unmet need with HT-001, aiming to redefine supportive treatment in oncodermatology.
Pharma & Biotech

Hoth Therapeutics makes strategic IP move to tackle radiation and targeted therapy skin toxicities

Hoth Therapeutics, Inc. has filed two provisional U.S. patents for its investigational therapy HT-001, aiming to address skin toxicities caused by radiation and targeted cancer therapies. The dual filings mark a deliberate expansion into oncology-adjacent dermatology, establishing a new intellectual property footprint around treatment-induced skin damage, including adverse effects linked to menin inhibitors. This signals

Read More
Pharma & Biotech

Can gut-restricted PDE4 inhibitors transform treatment for ulcerative colitis and Crohn’s?

Palisade Bio’s PALI-2108 secures a Japanese patent. Explore how this gut-targeted PDE4 inhibitor could change the game in ulcerative colitis and Crohn’s.

Read More
Medical Devices & Diagnostics

Can Positron Corporation’s $2m raise unlock growth in cardiac PET-CT imaging?

Positron Corporation raises $2 million to fund PET-CT system expansion in cardiac and oncology imaging. Can it scale fast enough to compete?

Read More
Pharma & Biotech

Can BioAtla’s Oz-V set a new standard in ROR2-targeted therapy for head and neck cancer?

BioAtla and GATC Health advance Ozuriftamab Vedotin into a Phase 3 trial for OPSCC via SPV financing. Discover how this targets cancer and aging together.

Read More
Medical Devices & Diagnostics

Intelligent Bio Solutions taps Syrma Johari to cut drug reader costs and prep for U.S. launch

INBS teams up with Syrma Johari to cut device costs, expand global output, and prep for a 2026 U.S. launch. Find out what this changes for fingerprint drug testing.

Read More
Pharma & Biotech

Serum Institute exits IXCHIQ rollout as Valneva resets LMIC strategy

Valneva ends its chikungunya vaccine deal with Serum Institute of India. Find out what this means for Asian access, LMIC rollout, and CEPI commitments.

Read More
Pharma & Biotech

Outlook’s bevacizumab for wet AMD rejected again: What’s holding back FDA approval?

FDA rejects Outlook Therapeutics’ ONS-5010 for wet AMD again. Find out what this means for U.S. approval and how European expansion could reshape strategy.

Read More
Pharma & Biotech

GoldenTree backs Alvotech with $100m financing to accelerate pipeline execution

Alvotech secures $100M loan to fund 2026 biosimilar launches and R&D. Find out how this financing reshapes its global strategy.

Read More
Pharma & Biotech

How XORTX is linking gout to genetics and reshaping the future of precision uric acid therapies

XORTX is using new genetic research to strengthen its case for oxypurinol in gout and kidney disease. Find out how this could shape the future of precision nephrology.

Read More